Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28131327 | 0.98 | MAPT (0.52) | MAPTKDM4ECYP19A1TBXAS1LOXL2 | |
| SCHEMBL3817375 | 0.85 | LOXL2 (0.64) | MAPTKDM4ELOXL2CYP3A4LMNA | |
| SCHEMBL5537149 | 0.84 | CYP19A1 (0.54) | MAPTKDM4ECYP19A1TBXAS1LOXL2 | |
| SCHEMBL5542601 | 0.81 | CYP19A1 (0.51) | MAPTKDM4ECYP19A1TBXAS1LOXL2 | |
| SCHEMBL3136413 | 0.81 | KDM4E (0.56) | MAPTKDM4ECYP19A1TBXAS1LOXL2 | |
| SCHEMBL5543653 | 0.80 | CYP19A1 (0.50) | MAPTKDM4ECYP19A1TBXAS1LOXL2 | |
| SCHEMBL3288710 | 0.79 | LOXL2 (0.74) | MAPTKDM4ECYP19A1TBXAS1LOXL2 | |
| SCHEMBL1282250 | 0.79 | MAPT (0.54) | MAPTKDM4ECYP19A1TBXAS1LOXL2 | |
| SCHEMBL12992933 | 0.79 | MAPT (0.54) | MAPTKDM4ECYP19A1TBXAS1LOXL2 | |
| SCHEMBL6629717 | 0.79 | MAPT (0.54) | MAPTKDM4ECYP19A1TBXAS1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| CN-101421257-A | Agents that disrupt cellular replication and their use in inhibiting pathological conditions | EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) | 2009-04-29 | — | — | CN | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| WO-2024096067-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN | 第一工業製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096066-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | 第一工業製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| EP-4361148-A1 | HETEROCYCLOALKYL-SUBSTITUTED POLYHETEROAZOLE DERIVATIVE AS MEDICAL DRUG FOR TREATMENT AND/OR PREVENTION OF RS VIRUS INFECTIOUS DISEASE | Albius Sciences Alpha Private Limited (SG) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024071370-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | 第一工業製薬株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024071371-A1 | HETEROCYCLIC COMPOUND | ユビエンス株式会社 | 2024-04-04 | — | — | WO | disclosed |
| CN-117730079-A | Heterocyclyl-substituted polyheterazoles derivatives as medicaments for the treatment and/or prophylaxis of RSV infections | 亚博思生物科技(第一)有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024029630-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | 第一工業製薬株式会社 | 2024-02-08 | — | — | WO | disclosed |
| EP-4261830-A1 | NOVEL PEPTIDOMIMETIC COMPOUND AND DESIGN | Oita University Institute of Advanced Medicine, Inc. (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2002048116-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAPT 4117/4885KDM4E 4854/4885CYP19A1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.